About Swasthya AI | Backed by 100X.VC

OncoClarity develops a cancer monitoring platform that integrates longitudinal clinical, genomic, and patient-reported outcomes data to provide personalized health insights for patients and actionable information for healthcare providers. This platform addresses the challenge of fragmented health data by enabling standardized care and informed clinical decision-making in oncology.

```xml <problem> Cancer research and treatment are hindered by fragmented and siloed health data, making it difficult to gain comprehensive insights into disease progression and treatment effectiveness, especially for diverse populations. The lack of integrated clinical, genomic, and patient-reported data limits the ability to personalize treatment plans and accelerate drug discovery. </problem> <solution> OncoClarity offers a cancer monitoring platform that integrates longitudinal clinical data, genomic information, and patient-reported outcomes, providing a comprehensive view of the patient journey. By aggregating data from diverse sources, including EMRs, genomic sequencing, and patient surveys, the platform enables personalized health insights and informed clinical decision-making. The platform facilitates target identification, enhances clinical trial design, and provides real-world evidence to accelerate drug discovery and improve patient outcomes, particularly within Asian and emerging economies. OncoClarity's integrated datasets help researchers identify potential targets, design inclusive clinical trials, and optimize treatment protocols. </solution> <features> - Aggregates longitudinal clinical data sourced from EMRs, genomics and transcriptomics data, and patient-reported outcomes data (ePROM). - Includes broad panel NGS data, whole genome sequence data, and RNA-seq data. - Incorporates imaging data, including histopathology slides and radiological images (CT, PET-CT, Mammography, etc.). - Provides access to over 1.5 million cancer patients' longitudinal records. - Offers access to over 20,000 whole exome sequence raw data sets and 90,000 tissue samples across biobanks. - Facilitates target identification and validation for specific research questions. - Enhances patient recruitment and stratification for clinical trials. - Enables comparative research for identifying unmet needs and protocol optimization studies. </features> <target_audience> The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers focused on oncology research, drug discovery, and personalized medicine, particularly those working with Asian patient populations. </target_audience> ```

What does Swasthya AI | Backed by 100X.VC do?

Where is Swasthya AI | Backed by 100X.VC located?

Swasthya AI | Backed by 100X.VC is based in Mumbai, India.

When was Swasthya AI | Backed by 100X.VC founded?

Swasthya AI | Backed by 100X.VC was founded in 2021.

How much funding has Swasthya AI | Backed by 100X.VC raised?

Swasthya AI | Backed by 100X.VC has raised 170000.

Location

Mumbai, India

Founded

2021

Funding

170000

Employees

9 employees

Major Investors

Google for Startups

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Swasthya AI | Backed by 100X.VC

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

swasthya.ai 1K+

Crunchbase

Founded 2021 – Mumbai, India

Funding

Estimated Funding

$100K+

Major Investors

Google for Startups

Team (5+)

No team information available.

Company Description

Problem

Cancer research and treatment are hindered by fragmented and siloed health data, making it difficult to gain comprehensive insights into disease progression and treatment effectiveness, especially for diverse populations. The lack of integrated clinical, genomic, and patient-reported data limits the ability to personalize treatment plans and accelerate drug discovery.

Solution

OncoClarity offers a cancer monitoring platform that integrates longitudinal clinical data, genomic information, and patient-reported outcomes, providing a comprehensive view of the patient journey. By aggregating data from diverse sources, including EMRs, genomic sequencing, and patient surveys, the platform enables personalized health insights and informed clinical decision-making. The platform facilitates target identification, enhances clinical trial design, and provides real-world evidence to accelerate drug discovery and improve patient outcomes, particularly within Asian and emerging economies. OncoClarity's integrated datasets help researchers identify potential targets, design inclusive clinical trials, and optimize treatment protocols.

Features

Aggregates longitudinal clinical data sourced from EMRs, genomics and transcriptomics data, and patient-reported outcomes data (ePROM).

Includes broad panel NGS data, whole genome sequence data, and RNA-seq data.

Incorporates imaging data, including histopathology slides and radiological images (CT, PET-CT, Mammography, etc.).

Provides access to over 1.5 million cancer patients' longitudinal records.

Offers access to over 20,000 whole exome sequence raw data sets and 90,000 tissue samples across biobanks.

Facilitates target identification and validation for specific research questions.

Enhances patient recruitment and stratification for clinical trials.

Enables comparative research for identifying unmet needs and protocol optimization studies.

Target Audience

The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers focused on oncology research, drug discovery, and personalized medicine, particularly those working with Asian patient populations.